LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Merck & Co Inc.

Fechado

SetorSaúde

78.94 1.77

Visão Geral

Variação de preço das ações

24h

Atual

Mín

78.73

Máximo

78.99

Indicadores-chave

By Trading Economics

Rendimento

1.3B

5.1B

Vendas

-95M

16B

P/E

Médio do Setor

11.083

51.198

EPS

2.22

Rendimento de Dividendos

4.25

Margem de lucro

32.745

Funcionários

73,000

EBITDA

386M

7.3B

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+27.55% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.25%

2.40%

Próximos Ganhos

29 de jul. de 2025

Próxima data de dividendos

8 de jul. de 2025

Próxima data de ex-dividendo

16 de jun. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-21B

191B

Abertura anterior

77.17

Fecho anterior

78.94

Sentimento de Notícias

By Acuity

38%

62%

120 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bearish Evidence

Merck & Co Inc. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

9 de abr. de 2025, 18:18 UTC

Grandes Movimentos do Mercado

Pharma Shares Reverse Losses After Tariff Pause

9 de abr. de 2025, 09:39 UTC

Grandes Movimentos do Mercado

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

4 de fev. de 2025, 12:33 UTC

Ganhos

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4 de fev. de 2025, 11:57 UTC

Ganhos

Merck 4Q Sales Increase Results in Swing to Profit

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New -2-

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

12 de mai. de 2025, 17:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

29 de abr. de 2025, 09:30 UTC

Principais Notícias

Merck to Spend $1 Billion on New Factory to Make U.S. Supplies of Blockbuster Drug -- WSJ

27 de abr. de 2025, 11:00 UTC

Principais Notícias

Wall Street's New Tariff Safe Haven: High-Tax Biotech Stocks -- Heard on the Street -- WSJ

24 de abr. de 2025, 20:08 UTC

Ganhos

Gilead Sciences Earnings Were Solid. How the S&P 500's No. 1 Health Stock Did. -- Barrons.com

24 de abr. de 2025, 16:05 UTC

Principais Notícias
Ganhos

Merck Cuts 2025 Outlook on Tariffs, Charges -- Update

24 de abr. de 2025, 14:36 UTC

Conversa de Mercado
Ganhos

Merck's Challenges with Gardasil in China Continue -- Market Talk

24 de abr. de 2025, 14:10 UTC

Conversa de Mercado
Ganhos

Merck's Mostly Steady Guidance Sees Current Tariffs Being Absorbed -- Market Talk

24 de abr. de 2025, 11:35 UTC

Ganhos

Merck Lowers Earnings Guidance and Says Tariffs Will Hit Margins -- Barrons.com

24 de abr. de 2025, 10:58 UTC

Principais Notícias
Ganhos

Merck 1Q Net Up, But 2025 Adj EPS View Cut on Tariffs, Charges

24 de abr. de 2025, 10:55 UTC

Ganhos

Merck Stock Rises After Earnings Even as Keytruda Sales Miss Estimates. Here's Why. -- Barrons.com

24 de abr. de 2025, 10:31 UTC

Ganhos

Merck: 2025 Outlook Absorbs Estimated $200 Million Additional Costs for Tariffs Implemented to Date >MRK

24 de abr. de 2025, 10:30 UTC

Ganhos

Merck 1Q Keytruda Sales $7.21B >MRK

24 de abr. de 2025, 10:30 UTC

Ganhos

Merck 1Q Pharmaceutical Sales $13.64B >MRK

24 de abr. de 2025, 10:30 UTC

Ganhos

Merck 1Q Keytruda Sales Up 4% >MRK

24 de abr. de 2025, 10:30 UTC

Ganhos

Merck 1Q Januvia/Janumet Sales Up 19% >MRK

24 de abr. de 2025, 10:30 UTC

Ganhos

Merck 1Q Pharmaceutical Sales Down 3% >MRK

24 de abr. de 2025, 10:30 UTC

Ganhos

Merck 1Q Gardasil/Gardasil 9 Sales $1.33B >MRK

24 de abr. de 2025, 10:30 UTC

Ganhos

Merck 1Q Januvia/Janumet Sales $796M >MRK

24 de abr. de 2025, 09:13 UTC

Ações em Alta

Stocks to Watch Thursday: IBM, Tesla, Chipotle -- WSJ

24 de mar. de 2025, 05:00 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5 de mar. de 2025, 19:42 UTC

Principais Notícias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5 de mar. de 2025, 10:30 UTC

Principais Notícias

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5 de fev. de 2025, 12:00 UTC

Principais Notícias

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4 de fev. de 2025, 14:48 UTC

Ganhos

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

Comparação entre Pares

Variação de preço

Merck & Co Inc. Previsão

Preço-alvo

By TipRanks

27.55% parte superior

Previsão para 12 meses

Média 100.73 USD  27.55%

Máximo 138 USD

Mínimo 82 USD

Com base em 17 analistas de Wall Street que oferecem metas de preço de 12 meses para Merck & Co Inc. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

17 ratings

10

Comprar

7

Manter

0

Vender

Pontuação Técnica

By Trading Central

76.03 / 83.28Suporte e Resistência

Curto Prazo

Bearish Evidence

Médio Prazo

Bearish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

120 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.